Presenting data from a multicenter study performed in Italy, Dr E. Rigoni of the Università degli Studi di Pavia, Pavia, Italy, suggested that monitoring myelin oligodendrocyte glycoprotein antibodies (MOG-Ab) in patients with acquired demyelinating syndromes (ADS) may not only have prognostic value but could also help guide disease management.
How useful are MOG antibodies as biomarkers in acquired demyelinating syndromes?
Ology Medical Education is a global provider of independent medical education. Its mission is to provide healthcare professionals with high-quality, trusted medical information with the aim of helping optimize patient care.
No responsibility is assumed by Ology Medical Education for any injury and/or damage to persons or property through negligence or otherwise, or from any use or operation of any methods, products, instructions, or ideas contained in the material herein. Because of rapid advances in the medical sciences, Ology Medical Education recommends that independent verification of diagnoses and drug dosages should be made. The opinions expressed do not reflect those of Ology Medical Education or the sponsor. Ology Medical Education assumes no liability for any material contained herein.